{
    "nct_id": "NCT03691909",
    "official_title": "A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis",
    "inclusion_criteria": "* Adult male or female between the ages of 18 and 65\n* Patients have active RA as confirmed by the following criteria:\n\n  * ≥ 6 swollen joints and ≥ 6 tender joints at screening (68-joint count)\n  * Abnormal CRP result OR abnormal ESR result at screening. Abnormal CRP result at screening OR abnormal ESR defined as:\n  * CRP > 4.9 mg/L or ESR > 10mm/hr for men, > 20mm/hr for women\n* Patients without current established treatment, or if being treated, patients who are on a stable dose of RA therapy regimen for ≥ 4 weeks prior to screening\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Inability to understand and provide signed informed consent\n\n  * Pregnancy, lactation, or, if female of childbearing potential, positive serum β-hCG at screening.\n  * Currently diagnosed any malignant neoplasm. Any patient who was successfully treated for cancer and has been disease-free, with no recurrence, for at least 5 years, will be considered.\n  * Uncontrolled systemic illness, including, but not limited to: hypertension (systolic >150 mm Hg or diastolic >95 mm Hg); diabetes; renal, hepatic, or cardiac failure or any laboratory abnormality that poses a safety risk to the subject such as:\n\n    * Hemoglobin ≤8.5 g/dL\n    * White blood cells (WBCs) ≤3,500/mm3 (3.5 G/L)\n    * Any other illness which, in the opinion of the investigator, characterizes the subject as not being a good candidate for the study\n  * Participation in another study with an investigational drug or device within 4 weeks prior to treatment or 5 half-lives of the investigational product used (whichever is longer).\n  * Positive results of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb), hepatitis C antibody (HCV Ab), and/or human immunodeficiency virus antibody (HIV Ab) tests at screening (excluding patients who are tested positive for HBsAb alone due to a hepatitis B vaccination).\n  * Positive history of Treponema pallidum.",
    "miscellaneous_criteria": ""
}